Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study

Digestive and Liver Disease

Volumn 47, Issue 5, 2015, Pages 405-410

  Coppo, Claudia ^a   Bonfanti, Daria ^a   Bo, Simona ^a   Giordanino, Chiara ^a   Gallo, Monica ^a   Cococcia, Sara ^a   Ciccone, Giovannino ^b   Smedile, Antonina ^a   Ciancio, Alessia ^a   Bugianesi, Elisabetta ^a   Fagoonee, Sharmila ^b   Pellicano, Rinaldo ^a   Rizzetto, Mario ^a   Saracco, Giorgio Maria ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic hepatitis C; Cirrhosis; Diabetes mellitus; Macroangiopathy; Microangiopathy

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; INSULIN; INSULIN SENSITIZING AGENT; INTERFERON; ORAL ANTIDIABETIC AGENT; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUTONOMIC NEUROPATHY; BODY MASS; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE DURATION; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART INFARCTION; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INCIDENCE; INSULIN TREATMENT; LIVER CANCER; LIVER CIRRHOSIS; LIVER HISTOLOGY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; TREATMENT DURATION; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEPATITIS C, CHRONIC; LIVER; PATHOLOGY;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84928829229     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.01.157     Document Type: Article

References (29)

1. Garcia-Compean D., Jaquez-Quintana J.O., Gonzalez-Gonzalez J.A., et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World Journal of Gastroenterology 2009, 15:280-288.
2. Holstein A., Hinze S., Thiessen E., et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. Journal of Gastroenterology and Hepatology 2002, 17:677-681.
3. Bianchi G., Marchesini G., Zoli M., et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994, 20:119-125.
4. Marchesini G., Ronchi M., Forlani G., et al. Cardiovascular disease in cirrhosis: a point-prevalence study in relation to glucose tolerance. American Journal of Gastroenterology 1999, 94:655-662.
5. Kuriyama S., Miwa Y., Fukushima H., et al. Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease. Journal of Clinical Biochemistry and Nutrition 2007, 40:116-122.
6. Mehta S.H., Brancati F.L., Sulkowski M.S., et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C infection in the United States. Annals of Internal Medicine 2000, 133:592-599.
7. Mehta S.H., Brancati F.L., Strathdee S.A., et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-56.
8. Petta S., Macaluso F.S., Craxì A. Cardiovascular diseases and HCV infection: a simple association or more?. Gut 2014, 63:369-375.
9. Knobler H., Schimanter R., Zifroni A., et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clinic Proceedings 2000, 75:355-359.
10. Persico M., Capasso M., Persico E., et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007, 46:1009-1015.
11. Hickman I.J., Powell E.E., Prins J.B., et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implication for therapy. Journal of Hepatology 2003, 39:1042-1048.
12. Ratziu V., Munteanu M., Charlotte F., et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. Journal of Hepatology 2003, 39:1049-1055.
13. Veldt B.J., Chen W., Heathcote J., et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-1862.
14. Hung C.H., Lee C.M., Wang J.H., et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. International Journal of Cancer 2011, 128:2344-2352.
15. Giordanino C., Ceretto S., Bo S., et al. Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study. Digestive and Liver Disease 2012, 44:406-412.
16. Chehadeh W., Kurien S.S., Abdella N., et al. Hepatitis C virus infection in a population with high incidence of type 2 diabetes: impact on diabetes complications. Journal of Infection and Public Health 2011, 4:200-206.
17. Joint National Committee The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Archives of Internal Medicine 1993, 153:154-183.
18. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28(Suppl. 1):S37-S42.
19. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. Journal of Hepatology 1995, 22:696-699.
20. Kettaneh A., Marcellin P., Douvin C., et al. Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients. A prospective study of 935 patients. Journal of Hepatology 2007, 46:628-634.
21. El Serag H.B., Everhart J.E. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002, 122:1822-1828.
22. Nishida T., Tsuji S., Tsuji M., et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. American Journal of Gastroenterology 2006, 101:70-75.
23. Huang Y.W., Yang S.S., Fu S.C., et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology 2014, 60:807-814.
24. Elkrief L., Chouinard P., Bendersky N., et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 2014, 60:823-831.
25. Fujiwara F., Ishii M., Taneichi H., et al. Low incidence of vascular complications in patients with diabetes mellitus associated with liver cirrhosis as compared with type 2 diabetes mellitus. Tohoku Journal of Experimental Medicine 2005, 205:327-334.
26. Melato M., Mucli E., Poldrugo F., et al. Stroke-cirrhosis relationship: an autopsy study in a heavy drinking population. Italian Journal of Gastroenterology 1991, 23:211-214.
27. Berzigotti A., Bonfiglioli A., Muscari A., et al. Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver International 2005, 25:331-336.
28. D'Arienzo A., Manguso F., Scaglione G., et al. Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scandinavian Journal of Gastroenterology 1998, 33:1213-1218.
29. Hsu Y.C., Lin J.T., Ho H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014, 59:1293-1302.